On the 5th, Jinseeker and medical tourism platform company Weedical signed a business agreement (MOU) to combine early cancer diagnosis technology and the ability to attract foreign patients.
Through this agreement, the two companies will integrate Jinseeker’s early cancer diagnosis technology and Weedical’s foreign patient attraction platform to provide differentiated services in the global medical tourism market. Jinseeker possesses early cancer diagnosis technology based on CRISPR gene scissors, and can detect cancer early through technology that precisely analyzes trace amounts of cancer genes in the blood. Weedical is a platform that provides customized medical services to foreign patients by utilizing its domestic hospital network, and plans to provide comprehensive healthcare services from early cancer diagnosis to treatment through this collaboration.
By integrating Jinseeker’s cancer early diagnosis kit into its platform, Weedical provides pre-health checkup and cancer risk analysis services to foreign patients. Through this, it is expected that patients will be able to understand their disease status more quickly and accurately, and strengthen the connection with medical institutions for treatment and prevention.
Through this agreement, Jinseeker plans to actively promote its cancer early diagnosis technology in overseas markets and attract foreign patients by utilizing Weedical’s platform. In addition, Jinseeker’s technology is useful not only for cancer diagnosis but also for preventive health management, and plans to expand its position in the global healthcare market through this.
Through this agreement, Weedical will be able to strengthen its premium healthcare solutions, including cancer diagnostic technology, and provide more specialized and customized medical services to foreign patients.
Jinseeker CEO Yesunghyeok said, “We expect that by attracting foreign patients with WediCal, our early cancer diagnosis technology will be recognized in the global market,” and “Through this collaboration, we will maximize the synergy between our innovative cancer diagnosis technology and medical tourism services.”
Weedical CEO Hee-chan Eom said, “The agreement with Jinseeker is an example of innovative technology and global medical tourism services coming together, and we will provide customers with a new healthcare experience through services that connect everything from cancer diagnosis to treatment.” He added, “We will continue to strengthen our competitiveness in the medical tourism market through cooperation with domestic and international partners.”
You must be logged in to post a comment.